Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 13/2016

Open Access 01-12-2016 | Review Article

SPECT and PET imaging of angiogenesis and arteriogenesis in pre-clinical models of myocardial ischemia and peripheral vascular disease

Authors: Geert Hendrikx, Stefan Vöö, Matthias Bauwens, Mark J. Post, Felix M. Mottaghy

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 13/2016

Login to get access

Abstract

Purpose

The extent of neovascularization determines the clinical outcome of coronary artery disease and other occlusive cardiovascular disorders. Monitoring of neovascularization is therefore highly important. This review article will elaborately discuss preclinical studies aimed at validating new nuclear angiogenesis and arteriogenesis tracers. Additionally, we will briefly address possible obstacles that should be considered when designing an arteriogenesis radiotracer.

Methods

A structured medline search was the base of this review, which gives an overview on different radiopharmaceuticals that have been evaluated in preclinical models.

Results

Neovascularization is a collective term used to indicate different processes such as angiogenesis and arteriogenesis. However, while it is assumed that sensitive detection through nuclear imaging will facilitate translation of successful therapeutic interventions in preclinical models to the bedside, we still lack specific tracers for neovascularization imaging. Most nuclear imaging research to date has focused on angiogenesis, leaving nuclear arteriogenesis imaging largely overlooked.

Conclusion

Although angiogenesis is the process which is best understood, there is no scarcity in theoretical targets for arteriogenesis imaging.
Literature
1.
Weissleder R, Ross BD, Rehemtulla A, Gambhir SS. General principles of molecular imaging. Molecular Imaging: Principles and practice. Shelton, CT: People’s Medical Publishing House-USA; 2010. p. 1–9.
2.
3.
4.
van der Have F, Vastenhouw B, Ramakers RM, et al. U-SPECT-II: an ultra-high-resolution device for molecular small-animal imaging. J Nucl Med. 2009;50:599–605.PubMedCrossRef
5.
Hendrikx G, Bauwens M, Wierts R, Mottaghy FM, Post MJ. Left ventricular function measurements in a mouse myocardial infarction model. Comparison between 3D-echocardiography and ECG-gated SPECT. Nuklearmedizin. 2016;55(3):115–22.
6.
7.
8.
Hendrikx G, De Saint-Hubert M, Dijkgraaf I, et al. Molecular imaging of angiogenesis after myocardial infarction by (111)In-DTPA-cNGR and (99m)Tc-sestamibi dual-isotope myocardial SPECT. EJNMMI Res. 2015;5:2.PubMedPubMedCentralCrossRef
9.
Dobrucki LW, de Muinck ED, Lindner JR, Sinusas AJ. Approaches to multimodality imaging of angiogenesis. J Nucl Med. 2010;51 Suppl 1:66S–79.PubMedCrossRef
10.
Stacy MR, Paeng JC, Sinusas AJ. The role of molecular imaging in the evaluation of myocardial and peripheral angiogenesis. Ann Nucl Med. 2015;29:217–23.PubMedPubMedCentralCrossRef
11.
Post MJ, Simons M. The rational phase of therapeutic angiogenesis. Minerva Cardioangiol. 2003;51:421–32.PubMed
12.
13.
Troidl K, Schaper W. Arteriogenesis versus angiogenesis in peripheral artery disease. Diabetes Metab Res Rev. 2012;28 Suppl 1:27–9.PubMedCrossRef
14.
Chalothorn D, Zhang H, Clayton JA, Thomas SA, Faber JE. Catecholamines augment collateral vessel growth and angiogenesis in hindlimb ischemia. Am J Physiol Heart Circ Physiol. 2005;289:H947–59.PubMedCrossRef
15.
van Royen N, Piek JJ, Schaper W, Fulton WF. A critical review of clinical arteriogenesis research. J Am Coll Cardiol. 2009;55:17–25.PubMedCrossRef
16.
Meoli DF, Sadeghi MM, Krassilnikova S, et al. Noninvasive imaging of myocardial angiogenesis following experimental myocardial infarction. J Clin Invest. 2004;113:1684–91.PubMedPubMedCentralCrossRef
17.
Gehring PJ, Hammond PB. The interrelationship between thallium and potassium in animals. J Pharmacol Exp Ther. 1967;155:187–201.PubMed
18.
Pagnanelli RA, Basso DA. Myocardial perfusion imaging with 201Tl. J Nucl Med Technol. 2010;38:1–3.PubMedCrossRef
19.
Earnshaw JJ, Hardy JG, Hopkinson BR, Makin GS. Non-invasive investigation of lower limb revascularisation using resting thallium peripheral perfusion imaging. Eur J Nucl Med. 1986;12:443–6.PubMedCrossRef
20.
Hamanaka D, Odori T, Maeda H, Ishii Y, Hayakawa K, Torizuka K. A quantitative assessment of scintigraphy of the legs using 201Tl. Eur J Nucl Med. 1984;9:12–6.PubMedCrossRef
21.
Oshima M, Akanabe H, Sakuma S, Yano T, Nishikimi N, Shionoya S. Quantification of leg muscle perfusion using thallium-201 single photon emission computed tomography. J Nucl Med. 1989;30:458–65.PubMed
22.
Siegel ME, Stewart CA. Thallium-201 peripheral perfusion scans: feasibility of single-dose, single-day, rest and stress study. AJR Am J Roentgenol. 1981;136:1179–83.PubMedCrossRef
23.
Kailasnath P, Sinusas AJ. Technetium-99m-labeled myocardial perfusion agents: are they better than thallium-201? Cardiol Rev. 2001;9:160–72.PubMedCrossRef
24.
Baggish AL, Boucher CA. Radiopharmaceutical agents for myocardial perfusion imaging. Circulation. 2008;118:1668–74.PubMedCrossRef
25.
Bajnok L, Kozlovszky B, Varga J, Antalffy J, Olvaszto S, Fulop Jr T. Technetium-99m sestamibi scintigraphy for the assessment of lower extremity ischaemia in peripheral arterial disease. Eur J Nucl Med. 1994;21:1326–32.PubMedCrossRef
26.
Kusmierek J, Dabrowski J, Bienkiewicz M, Szuminski R, Plachcinska A. Radionuclide assessment of lower limb perfusion using 99mTc-MIBI in early stages of atherosclerosis. Nucl Med Rev Cent East Eur. 2006;9:18–23.PubMed
27.
Miles KA, Barber RW, Wraight EP, Cooper M, Appleton DS. Leg muscle scintigraphy with 99Tcm-MIBI in the assessment of peripheral vascular (arterial) disease. Nucl Med Commun. 1992;13:593–603.PubMedCrossRef
28.
Beller GA, Glover DK, Edwards NC, Ruiz M, Simanis JP, Watson DD. 99mTc-sestamibi uptake and retention during myocardial ischemia and reperfusion. Circulation. 1993;87:2033–42.PubMedCrossRef
29.
Chiu ML, Kronauge JF, Piwnica-Worms D. Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxyisobutylisonitrile) technetium(I) in cultured mouse fibroblasts. J Nucl Med. 1990;31:1646–53.PubMed
30.
Piwnica-Worms D, Kronauge JF, Chiu ML. Uptake and retention of hexakis (2-methoxyisobutyl isonitrile) technetium(I) in cultured chick myocardial cells. Mitochondrial and plasma membrane potential dependence. Circulation. 1990;82:1826–38.PubMedCrossRef
31.
Piwnica-Worms D, Kronauge JF, Chiu ML. Enhancement by tetraphenylborate of technetium-99m-MIBI uptake kinetics and accumulation in cultured chick myocardial cells. J Nucl Med. 1991;32:1992–9.PubMed
32.
Li QS, Solot G, Frank TL, Wagner Jr HN, Becker LC. Myocardial redistribution of technetium-99m-methoxyisobutyl isonitrile (SESTAMIBI). J Nucl Med. 1990;31:1069–76.PubMed
33.
Okada RD, Glover D, Gaffney T, Williams S. Myocardial kinetics of technetium-99m-hexakis-2-methoxy-2-methylpropyl-isonitrile. Circulation. 1988;77:491–8.PubMedCrossRef
34.
Sinusas AJ, Bergin JD, Edwards NC, et al. Redistribution of 99mTc-sestamibi and 201Tl in the presence of a severe coronary artery stenosis. Circulation. 1994;89:2332–41.PubMedCrossRef
35.
Soyer H, Uslu I. A patient with peripheral arterial stenosis diagnosed with lower extremity perfusion scintigraphy. Clin Nucl Med. 2007;32:458–9.PubMedCrossRef
36.
Bonte FJ, Parkey RW, Graham KD, Moore J, Stokely EM. A new method for radionuclide imaging of myocardial infarcts. Radiology. 1974;110:473–4.PubMedCrossRef
37.
Onishi T, Kobayashi I, Onishi Y, et al. Evaluating microvascular obstruction after acute myocardial infarction using cardiac magnetic resonance imaging and 201-thallium and 99m-technetium pyrophosphate scintigraphy. Circ J. 2010;74:2633–40.PubMedCrossRef
38.
Forrest I, Hayes G, Smith A, Yip TC, Walker PM. Identification of clinically significant skeletal muscle necrosis by single photon emission computed tomography. Can J Surg. 1989;32:109–12.PubMed
39.
Yip TC, Houle S, Tittley JG, Walker PM. Quantification of skeletal muscle necrosis in the lower extremities using 99Tcm pyrophosphate with single photon emission computed tomography. Nucl Med Commun. 1992;13:47–52.PubMedCrossRef
40.
Schindler TH. Positron-emitting myocardial blood flow tracers and clinical potential. Prog Cardiovasc Dis. 2015;57:588–606.PubMedCrossRef
41.
Bengel FM. Leaving relativity behind: quantitative clinical perfusion imaging. J Am Coll Cardiol. 2011;58:749–51.PubMedCrossRef
42.
Schindler TH, Schelbert HR, Quercioli A, Dilsizian V. Cardiac PET imaging for the detection and monitoring of coronary artery disease and microvascular health. JACC Cardiovasc Imaging. 2010;3:623–40.PubMedCrossRef
43.
Depairon M, Depresseux JC, Petermans J, Zicot M. Assessment of flow and oxygen delivery to the lower extremity in arterial insufficiency: a PET-scan study comparison with other methods. Angiology. 1991;42:788–95.PubMedCrossRef
44.
Depairon M, Zicot M. The quantitation of blood flow/metabolism coupling at rest and after exercise in peripheral arterial insufficiency, using PET and 15–0 labeled tracers. Angiology. 1996;47:991–9.PubMedCrossRef
45.
Schmidt MA, Chakrabarti A, Shamim-Uzzaman Q, Kaciroti N, Koeppe RA, Rajagopalan S. Calf flow reserve with H(2)(15)O PET as a quantifiable index of lower extremity flow. J Nucl Med. 2003;44:915–9.PubMed
46.
Scremin OU, Figoni SF, Norman K, et al. Preamputation evaluation of lower-limb skeletal muscle perfusion with H(2) (15)O positron emission tomography. Am J Phys Med Rehabil. 2010;89:473–86.PubMedCrossRef
47.
Stacy MR, Zhou W, Sinusas AJ. Radiotracer imaging of peripheral vascular disease. J Nucl Med Technol. 2015;43:185–92.PubMedCrossRef
48.
Adachi I, Gaemperli O, Valenta I, et al. Assessment of myocardial perfusion by dynamic O-15-labeled water PET imaging: validation of a new fast factor analysis. J Nucl Cardiol. 2007;14:698–705.PubMedCrossRef
49.
Monahan WG, Tilbury RS, Laughlin JS. Uptake of 13 N-labeled ammonia. J Nucl Med. 1972;13:274–7.PubMed
50.
Xiangsong Z, Dianchao Y, Anwu T. Dynamic 13N-ammonia PET: a new imaging method to diagnose hypopituitarism. J Nucl Med. 2005;46:44–7.PubMed
51.
Harper PV, Lathrop KA, Krizek H, Lembares N, Stark V, Hoffer PB. Clinical feasibility of myocardial imaging with 13 NH 3. J Nucl Med. 1972;13:278–80.PubMed
52.
Phelps ME, Hoffman EJ, Coleman RE, et al. Tomographic images of blood pool and perfusion in brain and heart. J Nucl Med. 1976;17:603–12.PubMed
53.
Chow BJ, Beanlands RS, Lee A, et al. Treadmill exercise produces larger perfusion defects than dipyridamole stress N-13 ammonia positron emission tomography. J Am Coll Cardiol. 2006;47:411–6.PubMedCrossRef
54.
El Fakhri G, Kardan A, Sitek A, et al. Reproducibility and accuracy of quantitative myocardial blood flow assessment with (82)Rb PET: comparison with (13)N-ammonia PET. J Nucl Med. 2009;50:1062–71.PubMedPubMedCentralCrossRef
55.
Schelstraete K, Simons M, Deman J, Vermeulen FL, Goethals P, Bratzlavsky M. Visualization of muscles involved in unilateral tremor using 13N-ammonia and positron emission tomography. Eur J Nucl Med. 1982;7:422–5.PubMedCrossRef
56.
Tack CJ, van Gurp PJ, Holmes C, Goldstein DS. Local sympathetic denervation in painful diabetic neuropathy. Diabetes. 2002;51:3545–53.PubMedCrossRef
57.
Stewart RE, Schwaiger M, Molina E, et al. Comparison of rubidium-82 positron emission tomography and thallium-201 SPECT imaging for detection of coronary artery disease. Am J Cardiol. 1991;67:1303–10.PubMedCrossRef
58.
Yoshinaga K, Chow BJ, Williams K, et al. What is the prognostic value of myocardial perfusion imaging using rubidium-82 positron emission tomography? J Am Coll Cardiol. 2006;48:1029–39.PubMedCrossRef
59.
Nekolla SG, Saraste A. Novel F-18-labeled PET myocardial perfusion tracers: bench to bedside. Curr Cardiol Rep. 2011;13:145–50.PubMedCrossRef
60.
Yu M, Guaraldi MT, Mistry M, et al. BMS-747158-02: a novel PET myocardial perfusion imaging agent. J Nucl Cardiol. 2007;14:789–98.PubMedCrossRef
61.
Berman DS, Maddahi J, Tamarappoo BK, et al. Phase II safety and clinical comparison with single-photon emission computed tomography myocardial perfusion imaging for detection of coronary artery disease: flurpiridaz F 18 positron emission tomography. J Am Coll Cardiol. 2013;61:469–77.PubMedCrossRef
62.
Packard RR, Huang SC, Dahlbom M, Czernin J, Maddahi J. Absolute quantitation of myocardial blood flow in human subjects with or without myocardial ischemia using dynamic flurpiridaz F 18 PET. J Nucl Med. 2014;55:1438–44.PubMedPubMedCentralCrossRef
63.
Nekolla SG, Reder S, Saraste A, et al. Evaluation of the novel myocardial perfusion positron-emission tomography tracer 18F-BMS-747158-02: comparison to 13N-ammonia and validation with microspheres in a pig model. Circulation. 2009;119:2333–42.PubMedCrossRef
64.
Brevetti G, Giugliano G, Brevetti L, Hiatt WR. Inflammation in peripheral artery disease. Circulation. 2010;122:1862–75.PubMedCrossRef
65.
Seiler C, Stoller M, Pitt B, Meier P. The human coronary collateral circulation: development and clinical importance. Eur Heart J. 2013;34:2674–82.PubMedCrossRef
66.
Arras M, Ito WD, Scholz D, Winkler B, Schaper J, Schaper W. Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb. J Clin Invest. 1998;101:40–50.PubMedPubMedCentralCrossRef
67.
68.
Fam NP, Verma S, Kutryk M, Stewart DJ. Clinician guide to angiogenesis. Circulation. 2003;108:2613–8.PubMedCrossRef
69.
Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell. 2011;146:873–87.PubMedCrossRef
70.
Banai S, Jaklitsch MT, Shou M, et al. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation. 1994;89:2183–9.PubMedCrossRef
71.
Harada K, Friedman M, Lopez JJ, et al. Vascular endothelial growth factor administration in chronic myocardial ischemia. Am J Physiol. 1996;270:H1791–802.PubMed
72.
Rajanayagam MA, Shou M, Thirumurti V, et al. Intracoronary basic fibroblast growth factor enhances myocardial collateral perfusion in dogs. J Am Coll Cardiol. 2000;35:519–26.PubMedCrossRef
73.
Sellke FW, Li J, Stamler A, Lopez JJ, Thomas KA, Simons M. Angiogenesis induced by acidic fibroblast growth factor as an alternative method of revascularization for chronic myocardial ischemia. Surgery. 1996;120:182–8.PubMedCrossRef
74.
Yang HT, Deschenes MR, Ogilvie RW, Terjung RL. Basic fibroblast growth factor increases collateral blood flow in rats with femoral arterial ligation. Circ Res. 1996;79:62–9.PubMedCrossRef
75.
Hendel RC, Henry TD, Rocha-Singh K, et al. Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: evidence for a dose-dependent effect. Circulation. 2000;101:118–21.PubMedCrossRef
76.
Henry TD, Annex BH, McKendall GR, et al. The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation. 2003;107:1359–65.PubMedCrossRef
77.
Henry TD, Rocha-Singh K, Isner JM, et al. Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease. Am Heart J. 2001;142:872–80.PubMedCrossRef
78.
Simons M, Annex BH, Laham RJ, et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation. 2002;105:788–93.PubMedCrossRef
79.
80.
Annex BH, Simons M. Growth factor-induced therapeutic angiogenesis in the heart: protein therapy. Cardiovasc Res. 2005;65:649–55.PubMedCrossRef
81.
Dobrucki LW, Tsutsumi Y, Kalinowski L, et al. Analysis of angiogenesis induced by local IGF-1 expression after myocardial infarction using microSPECT-CT imaging. J Mol Cell Cardiol. 2010;48:1071–9.PubMedCrossRef
82.
Li S, Sinusas AJ, Dobrucki LW, Liu YH. New approach to quantification of molecularly targeted radiotracer uptake from hybrid cardiac SPECT/CT: methodology and validation. J Nucl Med. 2013;54:2175–81.PubMedCrossRef
83.
Lindsey ML, Escobar GP, Dobrucki LW, et al. Matrix metalloproteinase-9 gene deletion facilitates angiogenesis after myocardial infarction. Am J Physiol Heart Circ Physiol. 2006;290:H232–9.PubMedCrossRef
84.
Dimastromatteo J, Riou LM, Ahmadi M, et al. In vivo molecular imaging of myocardial angiogenesis using the alpha(v)beta3 integrin-targeted tracer 99mTc-RAFT-RGD. J Nucl Cardiol. 2010;17:435–43.PubMedCrossRef
85.
Dobrucki LW, Meoli DF, Hu J, Sadeghi MM, Sinusas AJ. Regional hypoxia correlates with the uptake of a radiolabeled targeted marker of angiogenesis in rat model of myocardial hypertrophy and ischemic injury. J Physiol Pharmacol. 2009;60 Suppl 4:117–23.PubMed
86.
Kalinowski L, Dobrucki LW, Meoli DF, et al. Targeted imaging of hypoxia-induced integrin activation in myocardium early after infarction. J Appl Physiol (1985). 2008;104:1504–12.CrossRef
87.
Johnson LL, Schofield L, Donahay T, Bouchard M, Poppas A, Haubner R. Radiolabeled arginine-glycine-aspartic acid peptides to image angiogenesis in swine model of hibernating myocardium. JACC Cardiovasc Imaging. 2008;1:500–10.PubMedPubMedCentralCrossRef
88.
Higuchi T, Bengel FM, Seidl S, et al. Assessment of alphavbeta3 integrin expression after myocardial infarction by positron emission tomography. Cardiovasc Res. 2008;78:395–403.PubMedCrossRef
89.
Laitinen I, Notni J, Pohle K, et al. Comparison of cyclic RGD peptides for alphavbeta3 integrin detection in a rat model of myocardial infarction. EJNMMI Res. 2013;3:38.PubMedPubMedCentralCrossRef
90.
Gao H, Lang L, Guo N, et al. PET imaging of angiogenesis after myocardial infarction/reperfusion using a one-step labeled integrin-targeted tracer 18F-AlF-NOTA-PRGD2. Eur J Nucl Med Mol Imaging. 2012;39:683–92.PubMedPubMedCentralCrossRef
91.
Eo JS, Paeng JC, Lee S, et al. Angiogenesis imaging in myocardial infarction using 68Ga-NOTA-RGD PET: characterization and application to therapeutic efficacy monitoring in rats. Coron Artery Dis. 2013;24:303–11.PubMedCrossRef
92.
Menichetti L, Kusmic C, Panetta D, et al. MicroPET/CT imaging of alphavbeta(3) integrin via a novel (6)(8)Ga-NOTA-RGD peptidomimetic conjugate in rat myocardial infarction. Eur J Nucl Med Mol Imaging. 2013;40:1265–74.PubMedCrossRef
93.
94.
Orbay H, Zhang Y, Valdovinos HF, et al. Positron emission tomography imaging of CD105 expression in a rat myocardial infarction model with (64)Cu-NOTA-TRC105. Am J Nucl Med Mol Imaging. 2014;4:1–9.
95.
96.
Dijkgraaf I, Boerman OC. Radionuclide imaging of tumor angiogenesis. Cancer Biother Radiopharm. 2009;24:637–47.PubMedCrossRef
97.
Dobrucki LW, Sinusas AJ. PET and SPECT in cardiovascular molecular imaging. Nat Rev Cardiol. 2010;7:38–47.PubMedCrossRef
98.
Sadeghi MM, Krassilnikova S, Zhang J, et al. Detection of injury-induced vascular remodeling by targeting activated alphavbeta3 integrin in vivo. Circulation. 2004;110:84–90.PubMedCrossRef
99.
Axelsson R, Bach-Gansmo T, Castell-Conesa J, McParland BJ. An open-label, multicenter, phase 2a study to assess the feasibility of imaging metastases in late-stage cancer patients with the alpha v beta 3-selective angiogenesis imaging agent 99mTc-NC100692. Acta Radiol. 2010;51:40–6.PubMedCrossRef
100.
Beer AJ, Grosu AL, Carlsen J, et al. [18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res. 2007;13:6610–6.PubMedCrossRef
101.
Beer AJ, Lorenzen S, Metz S, et al. Comparison of integrin alphaVbeta3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: a PET study using 18F-galacto-RGD and 18F-FDG. J Nucl Med. 2008;49:22–9.PubMedCrossRef
102.
Hou Y, Zhu Z, Jin X, Wang R, Xing B. Combined 18F-FDG PET/CT and 99mTc 3PRGD2 SPECT/CT imaging in a case of pituitary metastases. Clin Nucl Med. 2013;38:550–2.PubMedCrossRef
103.
Jin X, Meng Y, Zhu Z, Jing H, Li F. Elevated 99mTc 3PRGD2 activity in benign metastasizing leiomyoma. Clin Nucl Med. 2013;38:117–9.PubMedCrossRef
104.
Kenny LM, Coombes RC, Oulie I, et al. Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients. J Nucl Med. 2008;49:879–86.PubMedCrossRef
105.
Wan W, Guo N, Pan D, et al. First experience of 18F-alfatide in lung cancer patients using a new lyophilized kit for rapid radiofluorination. J Nucl Med. 2013;54:691–8.PubMedPubMedCentralCrossRef
106.
Zhu Z, Miao W, Li Q, et al. 99mTc-3PRGD2 for integrin receptor imaging of lung cancer: a multicenter study. J Nucl Med. 2012;53:716–22.PubMedCrossRef
107.
Li S, Peck-Radosavljevic M, Koller E, et al. Characterization of (123)I-vascular endothelial growth factor-binding sites expressed on human tumour cells: possible implication for tumour scintigraphy. Int J Cancer. 2001;91:789–96.PubMedCrossRef
108.
Morris MJ, Pandit-Taskar N, Divgi CR, et al. Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors. Clin Cancer Res. 2007;13:2707–13.PubMedCrossRef
109.
Santimaria M, Moscatelli G, Viale GL, et al. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res. 2003;9:571–9.PubMed
110.
Makowski MR, Ebersberger U, Nekolla S, Schwaiger M. In vivo molecular imaging of angiogenesis, targeting alphavbeta3 integrin expression, in a patient after acute myocardial infarction. Eur Heart J. 2008;29:2201.PubMedCrossRef
111.
Mozid AM, Holstensson M, Choudhury T, et al. Clinical feasibility study to detect angiogenesis following bone marrow stem cell transplantation in chronic ischaemic heart failure. Nucl Med Commun. 2014;35:839–48.PubMed
112.
Sun Y, Zeng Y, Zhu Y, et al. Application of (68)Ga-PRGD2 PET/CT for alphavbeta3-integrin imaging of myocardial infarction and stroke. Theranostics. 2014;4:778–86.PubMedPubMedCentralCrossRef
113.
114.
Pasqualini R, Koivunen E, Kain R, et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res. 2000;60:722–7.PubMedPubMedCentral
115.
Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 1998;279:377–80.PubMedCrossRef
116.
Colombo G, Curnis F, De Mori GM, et al. Structure-activity relationships of linear and cyclic peptides containing the NGR tumor-homing motif. J Biol Chem. 2002;277:47891–7.PubMedCrossRef
117.
Bruce D, Tan PH. Vascular endothelial growth factor receptors and the therapeutic targeting of angiogenesis in cancer: where do we go from here? Cell Commun Adhes. 2011;18:85–103.PubMed
118.
Moens S, Goveia J, Stapor PC, Cantelmo AR, Carmeliet P. The multifaceted activity of VEGF in angiogenesis - Implications for therapy responses. Cytokine Growth Factor Rev. 2014;25:473–82.PubMedCrossRef
119.
Hong H, Zhang Y, Orbay H, et al. Positron emission tomography imaging of tumor angiogenesis with a (61/64)Cu-labeled F(ab′)(2) antibody fragment. Mol Pharm. 2013;10:709–16.PubMedPubMedCentralCrossRef
120.
Zhang Y, Hong H, Nayak TR, et al. Imaging tumor angiogenesis in breast cancer experimental lung metastasis with positron emission tomography, near-infrared fluorescence, and bioluminescence. Angiogenesis. 2013;16:663–74.PubMedPubMedCentralCrossRef
121.
Zhang Y, Hong H, Orbay H, et al. PET imaging of CD105/endoglin expression with a (6)(1)/(6)(4)Cu-labeled Fab antibody fragment. Eur J Nucl Med Mol Imaging. 2013;40:759–67.PubMedPubMedCentralCrossRef
122.
Zhang Y, Hong H, Severin GW, et al. ImmunoPET and near-infrared fluorescence imaging of CD105 expression using a monoclonal antibody dual-labeled with (89)Zr and IRDye 800CW. Am J Transl Res. 2012;4:333–46.PubMedPubMedCentral
123.
Peach G, Griffin M, Jones KG, Thompson MM, Hinchliffe RJ. Diagnosis and management of peripheral arterial disease. BMJ. 2012;345, e5208.PubMedCrossRef
124.
Chaudru S, de Mullenheim PY, Le Faucheur A, Kaladji A, Jaquinandi V, Mahe G. Training to perform ankle-brachial index: systematic review and perspectives to improve teaching and learning. Eur J Vasc Endovasc Surg. 2016;51(2):240–7.PubMedCrossRef
125.
Madeddu P, Emanueli C, Spillmann F, et al. Murine models of myocardial and limb ischemia: diagnostic end-points and relevance to clinical problems. Vasc Pharmacol. 2006;45:281–301.CrossRef
126.
Dobrucki LW, Dione DP, Kalinowski L, et al. Serial noninvasive targeted imaging of peripheral angiogenesis: validation and application of a semiautomated quantitative approach. J Nucl Med. 2009;50:1356–63.PubMedPubMedCentralCrossRef
127.
Hua J, Dobrucki LW, Sadeghi MM, et al. Noninvasive imaging of angiogenesis with a 99mTc-labeled peptide targeted at alphavbeta3 integrin after murine hindlimb ischemia. Circulation. 2005;111:3255–60.PubMedCrossRef
128.
Jeong JM, Hong MK, Chang YS, et al. Preparation of a promising angiogenesis PET imaging agent: 68Ga-labeled c(RGDyK)-isothiocyanatobenzyl-1,4,7-triazacyclononane-1,4,7-triacetic acid and feasibility studies in mice. J Nucl Med. 2008;49:830–6.PubMedCrossRef
129.
Lee KH, Jung KH, Song SH, et al. Radiolabeled RGD uptake and alphav integrin expression is enhanced in ischemic murine hindlimbs. J Nucl Med. 2005;46:472–8.PubMed
130.
Almutairi A, Rossin R, Shokeen M, et al. Biodegradable dendritic positron-emitting nanoprobes for the noninvasive imaging of angiogenesis. Proc Natl Acad Sci U S A. 2009;106:685–90.PubMedPubMedCentralCrossRef
131.
Lu E, Wagner WR, Schellenberger U, et al. Targeted in vivo labeling of receptors for vascular endothelial growth factor: approach to identification of ischemic tissue. Circulation. 2003;108:97–103.PubMedCrossRef
132.
Willmann JK, Chen K, Wang H, et al. Monitoring of the biological response to murine hindlimb ischemia with 64Cu-labeled vascular endothelial growth factor-121 positron emission tomography. Circulation. 2008;117:915–22.PubMedPubMedCentralCrossRef
133.
Liu Y, Pressly ED, Abendschein DR, et al. Targeting angiogenesis using a C-type atrial natriuretic factor-conjugated nanoprobe and PET. J Nucl Med. 2011;52:1956–63.PubMedPubMedCentralCrossRef
134.
Orbay H, Hong H, Koch JM, et al. Pravastatin stimulates angiogenesis in a murine hindlimb ischemia model: a positron emission tomography imaging study with (64)Cu-NOTA-TRC105. Am J Transl Res. 2013;6:54–63.PubMedPubMedCentral
135.
Jones WS, Annex BH. Growth factors for therapeutic angiogenesis in peripheral arterial disease. Curr Opin Cardiol. 2007;22:458–63.PubMedCrossRef
136.
137.
Kim SH, Turnbull J, Guimond S. Extracellular matrix and cell signalling: the dynamic cooperation of integrin, proteoglycan and growth factor receptor. J Endocrinol. 2011;209:139–51.PubMedCrossRef
138.
Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci. 2001;114:853–65.PubMed
139.
Kong X, Wang X, Xu W, et al. Natriuretic peptide receptor a as a novel anticancer target. Cancer Res. 2008;68:249–56.PubMedCrossRef
140.
Maack T. The broad homeostatic role of natriuretic peptides. Arq Bras Endocrinol Metabol. 2006;50:198–207.PubMedCrossRef
141.
Pedram A, Razandi M, Levin ER. Natriuretic peptides suppress vascular endothelial cell growth factor signaling to angiogenesis. Endocrinology. 2001;142:1578–86.PubMed
142.
143.
Scholz D, Ziegelhoeffer T, Helisch A, et al. Contribution of arteriogenesis and angiogenesis to postocclusive hindlimb perfusion in mice. J Mol Cell Cardiol. 2002;34:775–87.PubMedCrossRef
144.
145.
Buschmann I, Schaper W. Arteriogenesis versus angiogenesis: two mechanisms of vessel growth. News Physiol Sci. 1999;14:121–5.PubMed
146.
Schirmer SH, van Nooijen FC, Piek JJ, van Royen N. Stimulation of collateral artery growth: travelling further down the road to clinical application. Heart. 2009;95:191–7.PubMedCrossRef
147.
Scholz D, Ito W, Fleming I, et al. Ultrastructure and molecular histology of rabbit hind-limb collateral artery growth (arteriogenesis). Virchows Arch. 2000;436:257–70.PubMedCrossRef
148.
van Royen N, Piek JJ, Buschmann I, Hoefer I, Voskuil M, Schaper W. Stimulation of arteriogenesis; a new concept for the treatment of arterial occlusive disease. Cardiovasc Res. 2001;49:543–53.PubMedCrossRef
149.
Vries MH, Wagenaar A, Verbruggen SE, et al. CXCL1 promotes arteriogenesis through enhanced monocyte recruitment into the peri-collateral space. Angiogenesis. 2015;18:163–71.PubMedCrossRef
150.
151.
Simons M, Bonow RO, Chronos NA, et al. Clinical trials in coronary angiogenesis: issues, problems, consensus: an expert panel summary. Circulation. 2000;102:E73–86.PubMedCrossRef
152.
153.
Li W, Tanaka K, Ihaya A, et al. Gene therapy for chronic myocardial ischemia using platelet-derived endothelial cell growth factor in dogs. Am J Physiol Heart Circ Physiol. 2005;288:H408–15.PubMedCrossRef
154.
Zuo H, Liu Z, Liu X, et al. CD151 gene delivery after myocardial infarction promotes functional neovascularization and activates FAK signaling. Mol Med. 2009;15:307–15.PubMedPubMedCentralCrossRef
155.
Kainuma S, Miyagawa S, Fukushima S, et al. Cell-sheet therapy with omentopexy promotes arteriogenesis and improves coronary circulation physiology in failing heart. Mol Ther. 2015;23:374–86.PubMedPubMedCentralCrossRef
156.
Crottogini A, Meckert PC, Vera Janavel G, et al. Arteriogenesis induced by intramyocardial vascular endothelial growth factor 165 gene transfer in chronically ischemic pigs. Hum Gene Ther. 2003;14:1307–18.PubMedCrossRef
157.
Vera Janavel G, Crottogini A, Cabeza Meckert P, et al. Plasmid-mediated VEGF gene transfer induces cardiomyogenesis and reduces myocardial infarct size in sheep. Gene Ther. 2006;13:1133–42.PubMedCrossRef
158.
Mack CA, Patel SR, Schwarz EA, et al. Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart. J Thorac Cardiovasc Surg. 1998;115:168–76. discussion 76–7.PubMedCrossRef
159.
Tio RA, Tkebuchava T, Scheuermann TH, et al. Intramyocardial gene therapy with naked DNA encoding vascular endothelial growth factor improves collateral flow to ischemic myocardium. Hum Gene Ther. 1999;10:2953–60.PubMedCrossRef
160.
Sato K, Laham RJ, Pearlman JD, et al. Efficacy of intracoronary versus intravenous FGF-2 in a pig model of chronic myocardial ischemia. Ann Thorac Surg. 2000;70:2113–8.PubMedCrossRef
161.
Laham RJ, Rezaee M, Post M, et al. Intrapericardial delivery of fibroblast growth factor-2 induces neovascularization in a porcine model of chronic myocardial ischemia. J Pharmacol Exp Ther. 2000;292:795–802.PubMed
162.
Stacy MR, da Yu Y, Maxfield MW, et al. Multimodality imaging approach for serial assessment of regional changes in lower extremity arteriogenesis and tissue perfusion in a porcine model of peripheral arterial disease. Circ Cardiovasc Imaging. 2014;7:92–9.PubMedCrossRef
163.
Hendrikx G, Vries MH, Bauwens M, et al. Comparison of LDPI to SPECT perfusion imaging using (99m)Tc-sestamibi and (99m)Tc-pyrophosphate in a murine ischemic hind limb model of neovascularization. EJNMMI Res. 2016;6:44.PubMedPubMedCentralCrossRef
164.
Buschmann I, Heil M, Jost M, Schaper W. Influence of inflammatory cytokines on arteriogenesis. Microcirculation. 2003;10:371–9.PubMedCrossRef
165.
van den Wijngaard JP, Schulten H, van Horssen P, et al. Porcine coronary collateral formation in the absence of a pressure gradient remote of the ischemic border zone. Am J Physiol Heart Circ Physiol. 2011;300:H1930–7.PubMedCrossRef
166.
Heil M, Ziegelhoeffer T, Pipp F, et al. Blood monocyte concentration is critical for enhancement of collateral artery growth. Am J Physiol Heart Circ Physiol. 2002;283:H2411–9.PubMedCrossRef
167.
Ito WD, Arras M, Winkler B, Scholz D, Schaper J, Schaper W. Monocyte chemotactic protein-1 increases collateral and peripheral conductance after femoral artery occlusion. Circ Res. 1997;80:829–37.PubMedCrossRef
168.
Oostendorp M, Douma K, Wagenaar A, et al. Molecular magnetic resonance imaging of myocardial angiogenesis after acute myocardial infarction. Circulation. 2010;121:775–83.PubMedCrossRef
169.
Buehler A, van Zandvoort MA, Stelt BJ, et al. cNGR: a novel homing sequence for CD13/APN targeted molecular imaging of murine cardiac angiogenesis in vivo. Arterioscler Thromb Vasc Biol. 2006;26:2681–7.PubMedCrossRef
Metadata
Title
SPECT and PET imaging of angiogenesis and arteriogenesis in pre-clinical models of myocardial ischemia and peripheral vascular disease
Authors
Geert Hendrikx
Stefan Vöö
Matthias Bauwens
Mark J. Post
Felix M. Mottaghy
Publication date
01-12-2016
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 13/2016
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-016-3480-8

Other articles of this Issue 13/2016

European Journal of Nuclear Medicine and Molecular Imaging 13/2016 Go to the issue

Original Article

Defining optimal tracer activities in pediatric oncologic whole-body 18F-FDG-PET/MRI

Original Article

Value and efficiency of sentinel lymph node diagnostics in patients with penile carcinoma with palpable inguinal lymph nodes as a new multimodal, minimally invasive approach

Review Article

Performance of cardiac cadmium-zinc-telluride gamma camera imaging in coronary artery disease: a review from the cardiovascular committee of the European Association of Nuclear Medicine (EANM)

Editorial

Effective and equivalent dose minimization for personnel in PET procedures: how far are we from the goal?

Editorial

Standardization of administered activities in paediatric nuclear medicine: the EANM perspective

Original Article

Assessment of the diagnostic accuracy of 18F-FDG PET/CT in prosthetic infective endocarditis and cardiac implantable electronic device infection: comparison of different interpretation criteria